NASDAQ:ONVO Organovo (ONVO) Stock Forecast, Price & News $1.33 -0.09 (-6.34%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.29▼$1.4850-Day Range$1.06▼$1.9052-Week Range$1.00▼$3.40Volume47,222 shsAverage Volume66,936 shsMarket Capitalization$11.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Organovo (NASDAQ:ONVO) StockOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Read More ONVO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONVO Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Coverage Initiated at StockNews.comSeptember 14, 2023 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Receives New Coverage from Analysts at StockNews.comSeptember 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.September 8, 2023 | finance.yahoo.comOrganovo to Participate in the H.C. Wainwright Global Investment ConferenceAugust 25, 2023 | finance.yahoo.comIs Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapAugust 23, 2023 | finance.yahoo.comOrganovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 DataAugust 16, 2023 | msn.comOnvo receives $3 million grant from PennDOT to enhance electric vehicle charging infrastructureJuly 29, 2023 | seekingalpha.comONVO Organovo Holdings, Inc.September 24, 2023 | Legacy Research (Ad)WARNING: Mandatory U.S. Dollar Recall is Weeks AwayIf you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.July 20, 2023 | msn.comOnvo introduces first public fast electric vehicle chargers on I-81 stretchJune 7, 2023 | fool.comOrganovo (NASDAQ: ONVO)March 21, 2023 | finance.yahoo.comOrganovo Announces FXR ProgramFebruary 10, 2023 | finance.yahoo.comWill Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely?October 25, 2022 | finance.yahoo.comOrganovo Holdings, Inc. (ONVO)October 17, 2022 | finance.yahoo.comTrends in 3D-Printing Materials Technology and the Global Market for the Most Promising New 3D-Printing Materials Applications - Yahoo FinanceOctober 12, 2022 | benzinga.comHuman Liver Models Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | D - BenzingaOctober 9, 2022 | globenewswire.com3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market - GlobeNewswireOctober 3, 2022 | seekingalpha.comARKG: Too Hard To Pin Down, Too Volatile For Comfort (BATS:ARKG) - Seeking AlphaSeptember 30, 2022 | prnewswire.comGlobal Laboratory Animal Models, 3D Cultures and Organoids Markets, 2019-2021 & 2022-2027 - Opportunities in Organoids in Drug Development, Personalized Medicine and Transplantational Medicine - PR NewswireSeptember 30, 2022 | businesswire.comGlobal Human Liver Model Market Report 2022: Emerging 3D and 2D Trends in Modeling Human Liver Disease in Vitro Fuel Growth - ResearchAndMarkets.com - Business WireSeptember 29, 2022 | businesswire.com3D Bioprinting Global Market Report 2022: Long-term Forecasts to 2026 & 2031 Featuring Organovo Holdings, Allevi, Cellink, Aspect Biosystems, & 3D Systems - ResearchAndMarkets.com - Business WireSeptember 23, 2022 | benzinga.comWhy Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket - American Vir - BenzingaSeptember 22, 2022 | uk.investing.comWhy Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UKSeptember 16, 2022 | nasdaq.comPre-market Movers: DWIN, SES, KSPN, NRBO, EPM… - NasdaqSeptember 16, 2022 | uk.investing.comWhy Applied Optoelectronics Is Trading Higher By Around 31%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UKSeptember 14, 2022 | rttnews.comPre-market Movers: DWIN, SES, KSPN, NRBO, EPM… - RTTNewsSeptember 6, 2022 | globenewswire.comOrganovo Announces Postponement of Annual Meeting of Stockholders - GlobeNewswireSee More Headlines Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address ONVO Company Calendar Last Earnings8/10/2023Today9/24/2023Next Earnings (Estimated)11/09/2023Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONVO CUSIPN/A CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,260,000.00 Net Margins-4,061.12% Pretax Margin-4,060.67% Return on Equity-97.16% Return on Assets-82.09% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.61 Sales & Book Value Annual Sales$370,000.00 Price / Sales31.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.76Miscellaneous Outstanding Shares8,720,000Free Float8,369,000Market Cap$11.60 million OptionableOptionable Beta0.88 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Keith E. Murphy (Age 51)Exec. Chairman Comp: $626.24kMs. Vaidehi Joshi (Age 36)Director of Discovery Biology & Director Comp: $91.4kMr. Thomas P. Hess CPA (Age 59)MBA, Pres & CFO Dr. Curtis M. Tyree Ph.D.Sr. VP of Strategy & Bus. Devel.Key CompetitorsEvaxion Biotech A/SNASDAQ:EVAXZIVO BioscienceNASDAQ:ZIVOAvalon GloboCareNASDAQ:ALBTSurrozenNASDAQ:SRZNEloxx PharmaceuticalsNASDAQ:ELOXView All Competitors ONVO Stock - Frequently Asked Questions How have ONVO shares performed in 2023? Organovo's stock was trading at $1.41 at the beginning of the year. Since then, ONVO stock has decreased by 5.7% and is now trading at $1.33. View the best growth stocks for 2023 here. When is Organovo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ONVO earnings forecast. How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) posted its quarterly earnings data on Thursday, August, 10th. The medical research company reported ($0.46) EPS for the quarter. The medical research company had revenue of $0.08 million for the quarter. Organovo had a negative net margin of 4,061.12% and a negative trailing twelve-month return on equity of 97.16%. When did Organovo's stock split? Shares of Organovo reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Taylor Crouch's approval rating as Organovo's CEO? 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK). What is Organovo's stock symbol? Organovo trades on the NASDAQ under the ticker symbol "ONVO." How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Organovo's stock price today? One share of ONVO stock can currently be purchased for approximately $1.33. How much money does Organovo make? Organovo (NASDAQ:ONVO) has a market capitalization of $11.60 million and generates $370,000.00 in revenue each year. The medical research company earns $-17,260,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. How can I contact Organovo? Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The official website for the company is www.organovo.com. The medical research company can be reached via phone at (858) 224-1000 or via email at ir@organovo.com. This page (NASDAQ:ONVO) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.